Join
Live feed
·
INSIDERFilingvia Quantisnow
Dyne Therapeutics Inc. logo

Chief Commercial Officer Friedl-Naderer Johanna sold $2,658 worth of shares (145 units at $18.33) as part of a pre-agreed trading plan, decreasing direct ownership by 0.09% to 154,208 units (SEC Form 4) to satisfy withholding obligation

ByQuantisnow·Wall Street's wire, on your screen.
DYN· Dyne Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DYN (Dyne Therapeutics Inc.) and more on Quantisnow.